Opioid Development Strategies In Pediatrics To Get FDA Advisory Panel Help
While FDA has long required pediatric analgesic studies, very few sponsors have managed to complete them, mainly due to enrollment challenges; advisory committees will offer recommendations on other designs that may bring a more successful result.
You may also be interested in...
Panelists appeared to have more questions than answers as the common cliché of 'more research is needed' dominated the two-day meeting.
FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.